Ocular surface disease exacerbated glaucoma

Article

The rationale for optimizing the ocular surface in glaucoma patients

Case series

Discussion

OSD caused by the long-term use of topical anti-glaucoma medication, can lead to conjunctival inflammation, foreshortening and shrinkage12 and severe symptomatic cicatrisation, which is indistinguishable from ocular cicatricial pemphigoid (OCP). The terms drug-induced cicatricial conjunctivitis (DICC) and pseudopemphigoid have been used.13

As discussed glaucoma therapy causes OSD, however, it is also apparent that severe OSD in turn exacerbates glaucoma. The prevalence of glaucoma in patients with severe OSD has been found to be 65.7%.14 Proposed mechanisms for raised IOP in patients with OSD are increased conjunctival inflammation in patients using anti-glaucoma medications, vascular aetiologies and inflammation of the trabecular meshwork, and in addition inflammation and scarring of the episclera and sclera thereby impairing the outflow facility of the eye.15 In support of this inflammatory theory, a higher rate of inflammatory cell infiltrates and fibroblasts have been found in conjunctival and trabeculectomy tissue samples from patients who are chronically exposed to preserved glaucoma medications.16

The aim of our treatment approach was to break the destructive cycle of events (OSD may potentiate glaucoma and vice versa) and achieve improved IOP control and a healthy ocular surface. In all four patients an improvement in the OSD resulted in an improvement in the IOP control and stabilization of the visual field. This obviated the need for surgical intervention, during the study period. We feel our approach was successful possibly due to decreased inflammation of the trabecular meshwork, conjunctiva, episclera and sclera leading to improved outflow facility of the eye.

If glaucoma filtration surgery is subsequently required in our patients, the improvement in the ocular surface may contribute to the increased likelihood of a successful surgical outcome.

It may be argued that the reduction in IOP may have been due to improved compliance with treatment for two reasons; firstly as patient care was transferred to a specialist consultant-led glaucoma service and secondly due to a reduction in ocular discomfort following treatment of the OSD. We feel that these scenarios are unlikely because all four patients reported good compliance with treatment prior to being referred to the service. Furthermore, we recognize the limitations of our small retrospective clinic-based observation and the need for large robust randomized studies to test our hypothesis.

Nevertheless, we feel that this is an important finding in a group of patients in whom management can be challenging; glaucoma in patients with severe OSD is often refractive to medical therapy14 and the surgical success of glaucoma filtering surgery is compromised in this group.17 Our study raises a new argument for maintaining increased awareness of the signs and symptoms of OSD in patients with glaucoma and emphasizes the importance of timely diagnosis and treatment of a phenomenon we describe as 'OSD exacerbated glaucoma'.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
© 2025 MJH Life Sciences

All rights reserved.